Page last updated: 2024-12-08
krh 1636
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
KRH 1636: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 465968 |
| CHEMBL ID | 2367715 |
| SCHEMBL ID | 4076464 |
| MeSH ID | M0449431 |
Synonyms (16)
| Synonym |
|---|
| n-[(1s)-4-guanidino-1-[[(1s)-1-(1-naphthyl)ethyl]carbamoyl]butyl]-4-[(2-pyridylmethylamino)methyl]benzamide |
| krh 1636 |
| krh-1636 |
| krh1636 |
| benzamide, n-[(1s)-4-[(aminoiminomethyl)amino]-1-[[[(1s)-1-(1-naphthalenyl)ethyl]amino]carbonyl]butyl]-4-[[(2-pyridinylmethyl)amino]methyl]- |
| n-[(2s)-5-(diaminomethylideneamino)-1-[[(1s)-1-naphthalen-1-ylethyl]amino]-1-oxopentan-2-yl]-4-[(pyridin-2-ylmethylamino)methyl]benzamide |
| CHEMBL2367715 , |
| SCHEMBL4076464 |
| 568526-77-2 |
| y4lkc2sd6w , |
| (2s)-5-carbamimidamido-n-((1s)-1-(naphthalen-1-yl)ethyl)-2-((4-((((pyridin-2-yl)methyl)amino)methyl)phenyl)formamido)pentanamide |
| n-((1s)-4-((aminoiminomethyl)amino)-1-((((1s)-1-(1-naphthalenyl)ethyl)amino)carbonyl)butyl)-4-(((2-pyridinylmethyl)amino)methyl)benzamide |
| benzamide, n-((1s)-4-((aminoiminomethyl)amino)-1-((((1s)-1-(1-naphthalenyl)ethyl)amino)carbonyl)butyl)-4-(((2-pyridinylmethyl)amino)methyl)- |
| unii-y4lkc2sd6w |
| n-((s)-5-guanidino-1-(((s)-1-(naphthalen-1-yl)ethyl)amino)-1-oxopentan-2-yl)-4-(((pyridin-2-ylmethyl)amino)methyl)benzamide |
| bdbm50458286 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| C-X-C chemokine receptor type 4 | Homo sapiens (human) | IC50 (µMol) | 0.0130 | 0.0003 | 0.2876 | 6.2000 | AID1383291 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (44)
Molecular Functions (13)
Ceullar Components (12)
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1383292 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication by MTT assay | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential. |
| AID1383295 | Plasma concentration in Wistar rat at 200 mg/ml/kg administered intraduodenal after 60 mins by LC-MS analysis | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential. |
| AID1383294 | Bioavailability in Wistar rat at 200 mg/ml/kg administered intraduodenal by LC-MS analysis | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential. |
| AID662533 | Displacement of [125I]-CXCL12 from CXCR4 expressed in human Jurkat cells at 10 uM relative to T140 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Pharmacophore-based small molecule CXCR4 ligands. |
| AID662535 | Cytotoxicity against human MT4 cells assessed as reduction of cell viability | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Pharmacophore-based small molecule CXCR4 ligands. |
| AID1383291 | Displacement of [125I]SDF-1alpha from CXCR4 in human MT4 cells after 2 hrs by scintillation counting analysis | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential. |
| AID662534 | Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Pharmacophore-based small molecule CXCR4 ligands. |
| AID1383293 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||